- Home
- BEATW vs NIO Comparison
BEATW vs NIO Comparison
Compare BEATW & NIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEATW
- NIO
- Stock Information
- Founded
- BEATW N/A
- NIO 2014
- Country
- BEATW United States
- NIO China
- Employees
- BEATW 20
- NIO N/A
- Industry
- BEATW Retail: Computer Software & Peripheral Equipment
- NIO Auto Manufacturing
- Sector
- BEATW Technology
- NIO Consumer Discretionary
- Exchange
- BEATW Nasdaq
- NIO Nasdaq
- Market Cap
- BEATW N/A
- NIO N/A
- IPO Year
- BEATW 2021
- NIO 2018
- Fundamental
- Price
- BEATW $0.57
- NIO $4.36
- Analyst Decision
- BEATW
- NIO Hold
- Analyst Count
- BEATW 0
- NIO 11
- Target Price
- BEATW N/A
- NIO $6.32
- AVG Volume (30 Days)
- BEATW N/A
- NIO 40.2M
- Earning Date
- BEATW N/A
- NIO 03-04-2025
- Dividend Yield
- BEATW N/A
- NIO N/A
- EPS Growth
- BEATW N/A
- NIO N/A
- EPS
- BEATW N/A
- NIO N/A
- Revenue
- BEATW N/A
- NIO $9,000,115,178.00
- Revenue This Year
- BEATW N/A
- NIO $22.74
- Revenue Next Year
- BEATW N/A
- NIO $49.79
- P/E Ratio
- BEATW N/A
- NIO N/A
- Revenue Growth
- BEATW N/A
- NIO 15.67
- 52 Week Low
- BEATW N/A
- NIO $3.61
- 52 Week High
- BEATW N/A
- NIO $7.71
- Technical
- Relative Strength Index (RSI)
- BEATW N/A
- NIO 47.76
- Support Level
- BEATW N/A
- NIO $4.01
- Resistance Level
- BEATW N/A
- NIO $4.20
- Average True Range (ATR)
- BEATW 0.00
- NIO 0.18
- MACD
- BEATW 0.00
- NIO -0.01
- Stochastic Oscillator
- BEATW 0.00
- NIO 38.89
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.